TABLE 3.

Dynamic Changes in Serum Cytokines Associated with Changes in Component Score of Symptom Severity, by Mixed-Effects Modeling

Mixed-Effects Model A. Increase in symptom severity (baseline to peak)
	Cytokines changes (baseline to day +8 after allo-HSCT)
	IL-6	IL-8	IL-10	IL-1RA	IL-1β	sTNF-R1	IL-12p40p70
Estimate*	1.112	0.294	0.390	0.147	1.613	1.133	−0.245
Standard error	0.505	0.393	0.357	0.500	0.517	0.915	1.842
P †	0.006	0.411	0.437	0.776	0.383	0.218	0.710

Mixed-Effects Model B. Change in symptom severity (baseline to +30 days)
	Cytokines changes (baseline to day +30 after allo-HSCT)
	IL-6	IL-8	IL-10	IL-1RA	IL-1β	sTNF-R1	IL-12p40p70
Estimate*	1.050	0.169	0.610	0.037	−0.135	1.367	−0.454
Standard error	0.245	0.194	0.369	0.304	0.564	0.650	0.294
P †	< .0001	0.383	0.100	0.903	0.812	0.036	0.124

Age, sex, race, disease status, infusion cell service, conditioning regimen, and infusion dose of allogeneic product were adjusted in all models. Selection of symptoms (pain, fatigue, sleep disturbance, drowsiness, poor appetite, and dry mouth) is based on the highest mean levels at symptom peak (day +11 of allo-HSCT).

Allo-HSCT indicates allogeneic hematopoietic stem cell transplantation; IL, interleukin; RA, receptor antagonist; sTNF-R1, soluble tumor necrosis factor receptor 1.

^*Estimate: The parameter estimated for a predictor. For log₁₀ transformed independent variables, it shows how the outcome changes when multiplying the predictor by 10. For example, the estimate of baseline log₁₀ IL-6 levels for the mean severity of the symptom cluster was 1.88 on a 0 to 10 scale, which meant that when the level of IL-6 increases by 10 times, there was a corresponding 1.88-unit increase in the mean symptom score.

^†Boldface indicates a statistically significant result.